Aptus Capital Advisors LLC Reduces Stake in Elevance Health, Inc. $ELV

Aptus Capital Advisors LLC trimmed its position in shares of Elevance Health, Inc. (NYSE:ELV) by 44.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,820 shares of the company’s stock after selling 25,068 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Elevance Health were worth $10,282,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Evergreen Wealth Management LLC lifted its position in shares of Elevance Health by 33.5% during the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock valued at $5,584,000 after buying an additional 4,336 shares during the last quarter. Blume Capital Management Inc. lifted its holdings in shares of Elevance Health by 236.7% during the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock valued at $1,986,000 after purchasing an additional 4,320 shares during the last quarter. Canoe Financial LP grew its stake in shares of Elevance Health by 18.1% during the third quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock worth $125,823,000 after acquiring an additional 59,743 shares during the last quarter. Synergy Asset Management LLC increased its position in shares of Elevance Health by 100.0% in the 3rd quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock valued at $33,712,000 after acquiring an additional 52,167 shares during the period. Finally, Delta Investment Management LLC purchased a new position in Elevance Health in the 3rd quarter worth $7,629,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

Shares of NYSE ELV opened at $289.56 on Friday. The stock has a fifty day moving average price of $344.64 and a 200 day moving average price of $335.01. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The company has a market cap of $63.91 billion, a PE ratio of 11.53, a P/E/G ratio of 1.58 and a beta of 0.51.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. During the same period in the prior year, the business posted $3.84 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is currently 27.23%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ELV. JPMorgan Chase & Co. increased their price objective on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Barclays dropped their price objective on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target for the company. in a report on Tuesday, February 3rd. Mizuho set a $413.00 target price on Elevance Health in a research note on Friday, January 9th. Finally, Robert W. Baird increased their target price on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.